Abstract 723P
Background
Recurrent/ metastatic (R/M) cervical cancer (CC) patients who failed previous therapy has limited treatment options, especially in those progressed on previous immunotherapy. Cadonilimab (AK104, a PD-1/CTLA-4 bi-specific antibody) has showed promising anti-tumor activity in R/M CC in those failed standard platinum-based chemotherapy. This study explored the efficacy and safety of AK104 plus chemotherapy to enhance tumor control in persistent R/M CC patients who failed previous immuno/chemotherapy.
Methods
This phase II study recruited patients with histologically confirmed CC who had failed previous immuno/chemotherapy for R/M disease. All patients received AK104 (10mg/kg, Q3W) with 4-6 cycles of investigator's choice of chemotherapy. The primary endpoint is ORR and PFS per RECIST1.1. The secondary endpoints includes DCR, OS and AE (CTCAE 5.0).
Results
By April 1, 2024, 21 patients were enrolled (median age: 52). All had history of radiotherapy (postoperative adjuvant or radical radiotherapy). For R/M disease, all patients had received previous platinum-based chemotherapy, and eight of them were treated with PD-1 inhibitors. The median follow-up was 9.4 months (range: 2.4-14.1). Of 21 patients, the ORR and DCR was 52.4% (11/21) and 95.2% (20/21), respectively. The mPFS was 6.2 months (95%CI[2.6-9.8]), the mPFS of 2nd and ≥ 3rd line treatment was 6.2 and 4.8 months, respectively. Median OS was not mature. In patients progressed on previous PD-1 inhibitors, 2 achieved partial response and 5 had stable disease, with the ORR of 25% (2/8) and DCR of 87.5% (7/8). 28.6% (6/21) of the patients had grade 3 AEs (4 leukocyte reduction, 1 anemia, 1 rash).
Conclusions
This study evaluated the efficacy and safety of AK104 plus chemotherapy on R/M CC patients who had failed previous immuno/chemotherapy. Our results showed preliminary improved efficacy comparing to previous monotherapy (COMPASSION-03 study, ORR of 32.3%). This demonstrated the promising anti-tumor effectiveness of AK104 in patients who failed previous immunotherapy, the potential of reversing drug resistance and good safety. Further studies in larger populations are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
X.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01